Baillie Gifford Acquires 4.99% Stake in Genmab A/S
Company Announcements

Baillie Gifford Acquires 4.99% Stake in Genmab A/S

Genmab (GMAB) has released an update.

Genmab A/S, a leading biotechnology firm, announced that Baillie Gifford & Co now holds 4.99% of its shares, signaling a significant investment by the major shareholder. The company, renowned for its innovative antibody therapeutics and ambitious vision to revolutionize treatment for cancer and other serious diseases by 2030, emphasizes its strong international presence and a 25-year legacy of technological advancements in the biotech industry.

For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskGenmab Reports Strong Growth and Strategic Advances
TipRanks Auto-Generated NewsdeskGenmab’s Revenue Soars with Strategic Developments
TipRanks Auto-Generated NewsdeskGenmab Sees Strong DARZALEX Sales in Q3 2024
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App